Correspondence 0001213900-25-005825 from Drugs Made In America Acquisition Corp. (DMAA, DMAAU) (CIK 0002028614) (DMAA)
Drugs Made In America Acquisition Corp. (DMAA, DMAAU) (CIK 0002028614)
Date: Jan. 23, 2025 · CIK: 0002028614 · Accession: 0001213900-25-005825
AI Filing Summary & Sentiment
File numbers found in text: 333-281170
Letter
Drugs Made In America Acquisition Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
January 23, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Manufacturing
100 F Street, N.E.
Washington, D.C. 20549
RE: Drugs Made In America Acquisition Corp. (the “Company”)
Post-Effective Amendment No. 2 to
Registration Statement on Form S-1
(File No. 333-281170) (the “Registration Statement”)
Ladies and Gentlemen:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m., Eastern time, on January 27, 2025, or as soon thereafter as practicable.
The Company hereby acknowledges that:
● Should the Securities and Exchange Commission (the “Commission”) or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
● The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
● The Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If there is any change in the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may be making an oral request of acceleration of the effectiveness of the Registration Statements in accordance with Rule 461 of Regulation C. Such request may be made by an executive officer of the Company or by any attorney from the Company’s U.S. counsel, Loeb & Loeb LLP.
[Signature page follows]
Very truly yours,
Drugs Made In America Acquisition Corp.
Show Raw Text
CORRESP
1
filename1.htm
Drugs Made In America Acquisition Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
January 23, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Manufacturing
100 F Street, N.E.
Washington, D.C. 20549
RE:
Drugs Made In America Acquisition Corp. (the “Company”)
Post-Effective Amendment No. 2 to
Registration Statement on Form S-1
(File No. 333-281170) (the “Registration Statement”)
Ladies and Gentlemen:
The Company hereby requests,
pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement
so that such Registration Statement will become effective as of 4:00 p.m., Eastern time, on January 27, 2025, or as soon thereafter as
practicable.
The Company hereby acknowledges
that:
●
Should the Securities and Exchange Commission (the “Commission”) or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
●
The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
●
The Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If there is any change in
the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may be making
an oral request of acceleration of the effectiveness of the Registration Statements in accordance with Rule 461 of Regulation C. Such
request may be made by an executive officer of the Company or by any attorney from the Company’s U.S. counsel, Loeb & Loeb LLP.
[Signature page follows]
Very truly yours,
Drugs Made In America Acquisition Corp.
By:
/s/ Lynn Stockwell
Name:
Lynn Stockwell
Title:
Chief Executive Officer